NYSE · CIK 0001962011
KAPA Kairos Pharma, LTD.
Insider trading from SEC Form 4. Last filing Dec 30, 2025. Close $0.81 on Oct 9, 2026, 0% from the 52-week low and -91% from the high.
Kairos Pharma, LTD. (KAPA) has 13 SEC Form 4 filings on file from 7 insiders, the latest filed on Dec 30, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
3 open-market trades have been scored at KAPA. The newest: Doug Samuelson (Chief Financial Officer) bought $3,750 of stock on Nov 22, 2024, filed Nov 25, 2024, scored 37 (weak). The largest of the 3 shown: John S Yu (CEO and Chairman) bought $5,760 on Nov 20, 2024, scored 35 (weak). 3 insiders bought within 14 days of each other around Nov 22, 2024.
KAPA closed at $0.81 on Oct 9, 2026, 0% above its 52-week low and 91% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Kairos Pharma, LTD., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 37Weak | Doug Samuelson Chief Financial Officer buy | $3,750 2,500 shares | +4% | - | |
| 25Weak | Ramachandran Murali VP of Research and Development buy | $318 200 shares | +0% | - | |
| 35Weak | John S Yu CEO and Chairman buy | $5,760 4,000 shares | +0% | - |
Transactions
Every row filed, 15 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 8, 2025 | Neil Bhowmick Chief Scientific Officer | AGrant or award COMMON STOCK | +171,756 | $0.00 | $0 | 1,311,739 | Dec 30, 2025 |
| Sep 16, 2025 | Hyun W. Bae director | AGrant or award COMMON STOCK | +10,000 | $0.00 | $0 | 54,286 | Dec 23, 2025 |
| Oct 8, 2025 | Hyun W. Bae director | AGrant or award COMMON STOCK | +19,084 | $0.00 | $0 | 73,370 | Dec 23, 2025 |
| Oct 8, 2025 | John S Yu CEO and Chairman | AGrant or award COMMON STOCK | +190,840 | $0.00 | $0 | 230,105 | Nov 26, 2025 |
| Oct 8, 2025 | Doug Samuelson Chief Financial Officer | AGrant or award COMMON STOCK | +152,672 | $0.00 | $0 | 293,039 | Nov 26, 2025 |
| Oct 8, 2025 | Rahul Singhvi director | AGrant or award COMMON STOCK | +19,084 | $0.00 | $0 | 49,204 | Nov 26, 2025 |
| Oct 8, 2025 | Ramachandran Murali VP of Research and Development | AGrant or award COMMON STOCK | +152,672 | $0.00 | $0 | 299,529 | Nov 26, 2025 |
| Sep 16, 2025 | Hansoo Michael Keyoung director | AGrant or award COMMON STOCK | +10,000 | $0.00 | $0 | 10,000 | Nov 26, 2025 |
| Oct 8, 2025 | Hansoo Michael Keyoung director | AGrant or award COMMON STOCK | +19,084 | $0.00 | $0 | 29,084 | Nov 26, 2025 |
| Jan 1, 2025 | Neil Bhowmick Chief Scientific Officer | AGrant or award COMMON STOCK | +14,000 | $0.00 | $0 | 1,139,983 | Apr 7, 2025 |
| Jan 1, 2025 | John S Yu CEO and Chairman | AGrant or award COMMON STOCK | +14,000 | $0.00 | $0 | 5,355,838 | Feb 24, 2025 |
| Jan 1, 2025 | Ramachandran Murali VP of Research and Development | AGrant or award COMMON STOCK | +14,000 | $0.00 | $0 | 147,057 | Feb 24, 2025 |
| Nov 25, 2024 | Ramachandran Murali VP of Research and Development | POpen-market purchase COMMON STOCK | +200 | $1.59 | $318 | 133,057 | Nov 25, 2024 |
| Nov 22, 2024 | Doug Samuelson Chief Financial Officer | POpen-market purchase COMMON STOCK | +2,500 | $1.50 | $3,750 | 60,796 | Nov 25, 2024 |
| Nov 20, 2024 | John S Yu CEO and Chairman | POpen-market purchase COMMON STOCK | +4,000 | $1.44 | $5,760 | 5,341,837 | Nov 21, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Hyun W. Baedirector
- Neil BhowmickChief Scientific Officer
- Hansoo Michael Keyoungdirector
- Ramachandran MuraliVP of Research and Development
- Doug SamuelsonChief Financial Officer
- Rahul Singhvidirector
- John S YuCEO and Chairman
Questions about KAPA
Answered from the filings on this page, as of the latest one.
Are insiders buying KAPA?
No. In the last 90 days no insider at Kairos Pharma, LTD. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade KAPA on the open market?
Doug Samuelson (Chief Financial Officer) bought $3,750 of KAPA on Nov 22, 2024 and filed the Form 4 on Nov 25, 2024. InsiderTell scored 37 (weak), with 3 insiders on the same side within 14 days.
How many insiders file Form 4 at Kairos Pharma, LTD.?
7 people have filed a Form 4 at Kairos Pharma, LTD., among them Hyun W. Bae (director), Neil Bhowmick (Chief Scientific Officer), Hansoo Michael Keyoung (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.